ChemoTech, an international life science company based in Lund, Sweden, was founded in 2015 by a team of experts in radiation physics, surgical oncology, and clinical development. Our R&D strategy emerged from recognizing that many adverse effects of traditional electrochemotherapy are caused by its destructive elements. This understanding led to the development of our technology, which prioritizes effective treatment while minimizing damage to healthy tissue.
Leveraging extensive experience in medical technology, clinical applications, and commercialization, ChemoTech focuses on creating innovative, less destructive therapies for tumours that improve quality of life and extend life expectancy for both humans and animals.
Our patented technology platform, TSE, is designed to revolutionize cancer treatment. It enhances the uptake of therapeutic molecules in cancerous tissue, enabling tumour-specific treatments with significantly lower doses of chemotherapy compared to conventional methods.
By avoiding immediate cell death (necrosis), TSE minimizes undesired side effects and adapts automatically to different tumours and their surrounding tissue. This innovation offers a safer and more precise approach to cancer therapy.
We aim to develop and market cost-effective, innovative solutions for treating tumours in both humans and animals. Our technology focuses on:
Our vision & mission
Our mission
We strive to establish new methods and innovations for treating cancers in areas of greatest need. Through efficient R&D and production, we aim to offer advanced treatments to both humans and animals, ensuring better outcomes where standard therapies fall short.
Our vision
Our vision is to become a leader in selected areas of cancer care, making a meaningful impact on patients who lack access to adequate treatments due to late diagnoses or outdated options. Over time, we aim to drive progress and hope for those facing the toughest cancer challenges.
Our business model comprises:
Our strategy is to build a global presence and develop sustainable revenue streams in both the Human Care and Animal Care divisions.
The development of TSE stems from the founders’ extensive expertise in oncology, surgery, and international business development. Unlike traditional approaches that aim to destroy cancer cells rapidly, we explored how to achieve controlled tumour cell death, improving the treatment process and outcomes.
Research and clinical studies have shown that many ablation techniques are effective only for small tumours (under 2–3 cm). Larger tumours often respond poorly to these treatments. By addressing these limitations, TSE offers a breakthrough in treating larger and more complex tumours, providing a better chance for successful outcomes.
We observed that ablation techniques in oncology shared similar limitations. In published studies, it was further demonstrated that good treatment results had a clear correlation with small tumours under 2–3 centimetres. When treating larger tumours, the treatment results were significantly worse, and a correlation between a good treatment result and the patient’s tumour size could be established.
Get in touch
Are you interested in our products?
Our team is here to help with any questions about our products, patents or anything else you may need help with.
This website uses cookies. If you continue to browse the website, you agree to the use of cookies.